

Johannes H Schulte

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7502101/publications.pdf>

Version: 2024-02-01

150
papers

8,981
citations

61687

45
h-index

53065

89
g-index

154
all docs

154
docs citations

154
times ranked

14026
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeted Analysis of Cell-free Circulating Tumor DNA is Suitable for Early Relapse and Actionable Target Detection in Patients with Neuroblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 1809-1820.	3.2	22
2	Circulating Cell-Free DNA Assessment in Biofluids from Children with Neuroblastoma Demonstrates Feasibility and Potential for Minimally Invasive Molecular Diagnostics. <i>Cancers</i> , 2022, 14, 2080.	1.7	6
3	Genomic Evolution and Personalized Therapy of an Infantile Fibrosarcoma Harboring an <i>NTRK</i> Oncogenic Fusion. <i>JCO Precision Oncology</i> , 2022, , .	1.5	4
4	Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells. <i>Molecular Cancer</i> , 2022, 21, .	7.9	21
5	Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against <i>MYCN</i> -amplified neuroblastoma. <i>International Journal of Cancer</i> , 2021, 148, 1219-1232.	2.3	13
6	Allogeneic hematopoietic stem cell transplantation from sibling and unrelated donors in pediatric patients with sickle cell disease—A single center experience. <i>Pediatric Transplantation</i> , 2021, 25, e13892.	0.5	5
7	Clinical Presentation and Management of a Dinutuximab Beta Extravasation in a Patient with Neuroblastoma. <i>Children</i> , 2021, 8, 91.	0.6	2
8	Efficacy of Brincidofovir in Pediatric Stem Cell Transplant Recipients With Adenovirus Infections. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, , .	0.6	2
9	Hemostatic Management in an Infant With Neuroblastoma and Severe Hemophilia B With Extended Half-life Recombinant Factor IX Fusion Protein. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, Publish Ahead of Print, .	0.3	0
10	CD28 Co-Stimulus Achieves Superior CAR T Cell Effector Function against Solid Tumors Than 4-1BB Co-Stimulus. <i>Cancers</i> , 2021, 13, 1050.	1.7	17
11	Eye Tumors in Childhood as First Sign of Tumor Predisposition Syndromes: Insights from an Observational Study Conducted in Germany and Austria. <i>Cancers</i> , 2021, 13, 1876.	1.7	7
12	The MicroRNA Landscape of <i>MYCN</i> -Amplified Neuroblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 647737.	1.3	12
13	ALK Inhibitors in Neuroblastoma: A Sprint from Bench to Bedside. <i>Clinical Cancer Research</i> , 2021, 27, 3507-3509.	3.2	6
14	A Reproducible Bioprinted 3D Tumor Model Serves as a Preselection Tool for CAR T Cell Therapy Optimization. <i>Frontiers in Immunology</i> , 2021, 12, 689697.	2.2	25
15	RARE-07. EFFICACY AND SAFETY OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION-POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS. <i>Neuro-Oncology</i> , 2021, 23, i42-i42.	0.6	0
16	Discovery of Spatial Peptide Signatures for Neuroblastoma Risk Assessment by MALDI Mass Spectrometry Imaging. <i>Cancers</i> , 2021, 13, 3184.	1.7	8
17	Hematopoietic stem cell transplantation in children and adolescents with <i>GATA2</i> -related myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2021, 56, 2732-2741.	1.3	24
18	GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma. , 2021, 9, e002923.		11

#	ARTICLE	IF	CITATIONS
19	Neuroblastoma Risk Assessment and Treatment Stratification with Hybrid Capture-Based Panel Sequencing. <i>Journal of Personalized Medicine</i> , 2021, 11, 691.	1.1	2
20	Inhibiting Lysine Demethylase 1A Improves L1CAM-Specific CAR T Cell Therapy by Unleashing Antigen-Independent Killing via the FAS-FASL Axis. <i>Cancers</i> , 2021, 13, 5489.	1.7	2
21	Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance. <i>PLoS Computational Biology</i> , 2021, 17, e1009515.	1.5	5
22	CTNI-58. EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT AND PEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION-POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS. <i>Neuro-Oncology</i> , 2021, 23, vi73-vi74.	0.6	1
23	Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions. <i>Nature Communications</i> , 2021, 12, 6804.	5.8	39
24	Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study. <i>Lancet Oncology</i> , The, 2021, 22, 1764-1776.	5.1	37
25	Personalisierte Medizin in der Kinderonkologie: Wo stehen wir heute?. <i>PÄdiatrie Up2date</i> , 2021, 16, 325-342.	0.0	0
26	Transmission of chromosomally integrated human herpes virus-6A via haploidentical stem cell transplantation poses a risk for virus reactivation and associated complications. <i>Bone Marrow Transplantation</i> , 2020, 55, 260-264.	1.3	2
27	Reflection of neuroblastoma intratumor heterogeneity in the new OHCâ€œNB1 disease model. <i>International Journal of Cancer</i> , 2020, 146, 1031-1041.	2.3	9
28	Small-Molecule Dual PLK1 and BRD4 Inhibitors are Active Against Preclinical Models of Pediatric Solid Tumors. <i>Translational Oncology</i> , 2020, 13, 221-232.	1.7	20
29	Donor selection in a pediatric stem cell transplantation cohort using PIRCHE and HLAâ€œDPB1 typing. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28127.	0.8	4
30	Extrachromosomal circular DNA drives oncogenic genome remodeling in neuroblastoma. <i>Nature Genetics</i> , 2020, 52, 29-34.	9.4	193
31	Enhancer hijacking determines extrachromosomal circular MYCN amplicon architecture in neuroblastoma. <i>Nature Communications</i> , 2020, 11, 5823.	5.8	104
32	Identification of RNA-Binding Proteins as Targetable Putative Oncogenes in Neuroblastoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5098.	1.8	16
33	Sinusoidal Obstruction Syndrome Following Myeloablative Therapy and Tranexamic Acid Treatment for Hemorrhage in Two Patients with Neuroblastoma. <i>Children</i> , 2020, 7, 198.	0.6	0
34	Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers. <i>Nature Genetics</i> , 2020, 52, 891-897.	9.4	273
35	Multiplexed Quantification of Four Neuroblastoma DNA Targets in a Single Droplet Digital PCR Reaction. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1309-1323.	1.2	11
36	N-Myc-induced metabolic rewiring creates novel therapeutic vulnerabilities in neuroblastoma. <i>Scientific Reports</i> , 2020, 10, 7157.	1.6	19

#	ARTICLE	IF	CITATIONS
37	Tumor-Derived Extracellular Vesicles Impair CD171-Specific CD4+ CAR T Cell Efficacy. <i>Frontiers in Immunology</i> , 2020, 11, 531.	2.2	20
38	Central memory phenotype drives success of checkpoint inhibition in combination with CAR T cells. <i>Molecular Carcinogenesis</i> , 2020, 59, 724-735.	1.3	8
39	CTNI-67. EFFICACY AND SAFETY OF LAROTRECTINIB IN PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS: AN EXPANDED DATASET. <i>Neuro-Oncology</i> , 2020, 22, ii58-ii58.	0.6	2
40	Lineage-restricted sympathoadrenal progenitors confer neuroblastoma origin and its tumorigenicity. <i>Oncotarget</i> , 2020, 11, 2357-2371.	0.8	7
41	Oncogenic <i>ALK^{F1174L}</i> drives tumorigenesis in cutaneous squamous cell carcinoma. <i>Life Science Alliance</i> , 2020, 3, e201900601.	1.3	4
42	HLA-haploidentical hematopoietic stem cell transplantation in pediatric patients with hemoglobinopathies: current practice and new approaches. <i>Bone Marrow Transplantation</i> , 2019, 54, 743-748.	1.3	22
43	Expression of the Neuroblastoma-Associated ALK-F1174L Activating Mutation During Embryogenesis Impairs the Differentiation of Neural Crest Progenitors in Sympathetic Ganglia. <i>Frontiers in Oncology</i> , 2019, 9, 275.	1.3	10
44	ADCC can improve graft vs leukemia effect after T- and B-cell depleted haploidentical stem cell transplantation in pediatric B-lineage ALL. <i>Bone Marrow Transplantation</i> , 2019, 54, 689-693.	1.3	5
45	CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing. <i>BMC Cancer</i> , 2019, 19, 895.	1.1	40
46	Increased Anaplastic Lymphoma Kinase Activity Induces a Poorly Differentiated Thyroid Carcinoma in Mice. <i>Thyroid</i> , 2019, 29, 1438-1446.	2.4	5
47	Haploidentical CD3 or $\hat{\pm}/\hat{1}^2$ T-cell depleted HSCT in advanced stage sickle cell disease. <i>Bone Marrow Transplantation</i> , 2019, 54, 1859-1867.	1.3	39
48	The small molecule Bcl-2/Mcl-1 inhibitor TW-37 shows single-agent cytotoxicity in neuroblastoma cell lines. <i>BMC Cancer</i> , 2019, 19, 243.	1.1	18
49	Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma. <i>Cancer Letters</i> , 2019, 445, 24-33.	3.2	22
50	ALK positively regulates MYCN activity through repression of HBP1 expression. <i>Oncogene</i> , 2019, 38, 2690-2705.	2.6	17
51	Prohibitin promotes dedifferentiation and is a potential therapeutic target in neuroblastoma. <i>JCI Insight</i> , 2019, 4, .	2.3	20
52	LIN28B enhanced tumorigenesis in an autochthonous KRASG12V-driven lung carcinoma mouse model. <i>Oncogene</i> , 2018, 37, 2746-2756.	2.6	16
53	The Expanding World of N-MYC-Driven Tumors. <i>Cancer Discovery</i> , 2018, 8, 150-163.	7.7	170
54	TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets. <i>Nature Communications</i> , 2018, 9, 4866.	5.8	91

#	ARTICLE	IF	CITATIONS
55	A mechanistic classification of clinical phenotypes in neuroblastoma. <i>Science</i> , 2018, 362, 1165-1170.	6.0	213
56	Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients. <i>JCI Insight</i> , 2018, 3, .	2.3	28
57	Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma. <i>Oncotarget</i> , 2018, 9, 2304-2319.	0.8	51
58	Overexpression of Lin28b in Neural Stem Cells is Insufficient for Brain Tumor Formation, but Induces Pathological Lobulation of the Developing Cerebellum. <i>Cerebellum</i> , 2017, 16, 122-131.	1.4	14
59	2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors. <i>Klinische Padiatrie</i> , 2017, 229, 147-167.	0.2	76
60	Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 1-11.	2.5	28
61	Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	48
62	Life-threatening systemic rotavirus infection after vaccination in severe combined immunodeficiency (<sc>SCID</sc>). <i>Pediatric Allergy and Immunology</i> , 2017, 28, 841-843.	1.1	12
63	From class waivers to precision medicine in paediatric oncology. <i>Lancet Oncology</i> , The, 2017, 18, e394-e404.	5.1	45
64	Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines. <i>Clinical and Experimental Ophthalmology</i> , 2017, 45, 288-296.	1.3	8
65	Targeting tachykinin receptors in neuroblastoma. <i>Oncotarget</i> , 2017, 8, 430-443.	0.8	19
66	The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models. <i>Oncotarget</i> , 2017, 8, 6730-6741.	0.8	34
67	RITA displays anti-tumor activity in medulloblastomas independent of <i>TP53</i> status. <i>Oncotarget</i> , 2017, 8, 27882-27891.	0.8	4
68	Immune response modulation by Galectin-1 in a transgenic model of neuroblastoma. <i>Oncolmmunology</i> , 2016, 5, e1131378.	2.1	18
69	Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study. <i>European Journal of Cancer</i> , 2016, 65, 91-101.	1.3	262
70	Development of Portalsite Metastases Following Thoracoscopic Resection of a Neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2016, 63, 149-151.	0.8	10
71	Towards diagnostic application of non-coding RNAs in neuroblastoma. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 1307-1313.	1.5	2
72	Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition. <i>Clinical Cancer Research</i> , 2016, 22, 2470-2481.	3.2	147

#	ARTICLE	IF	CITATIONS
73	MYCN and HDAC5 transcriptionally repress <i>CD9</i> to trigger invasion and metastasis in neuroblastoma. <i>Oncotarget</i> , 2016, 7, 66344-66359.	0.8	30
74	Characterization of pancreatic glucagon-producing tumors and pituitary gland tumors in transgenic mice overexpressing <i>MYCN</i> in <i>hGFAP</i> -positive cells. <i>Oncotarget</i> , 2016, 7, 74415-74426.	0.8	21
75	Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma. <i>Oncotarget</i> , 2016, 7, 1960-1972.	0.8	26
76	The mitochondrial genetic landscape in neuroblastoma from tumor initiation to relapse. <i>Oncotarget</i> , 2016, 7, 6620-6625.	0.8	8
77	<i>M</i> ^R 34a deficiency accelerates medulloblastoma formation <i>in vivo</i> . <i>International Journal of Cancer</i> , 2015, 136, 2293-2303.	2.3	40
78	Neuroblastoma. <i>Critical Reviews in Oncogenesis</i> , 2015, 20, 245-270.	0.2	40
79	Temporal proteomics of NGF-TrkA signaling identifies an inhibitory role for the E3 ligase Cbl-b in neuroblastoma cell differentiation. <i>Science Signaling</i> , 2015, 8, ra40.	1.6	64
80	MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 222-230.	3.3	16
81	Absence of telomerase reverse transcriptase promoter mutations in neuroblastoma. <i>Biomedical Reports</i> , 2015, 3, 443-446.	0.9	25
82	MYCN-driven regulatory mechanisms controlling LIN28B in neuroblastoma. <i>Cancer Letters</i> , 2015, 366, 123-132.	3.2	51
83	Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. <i>Nature Genetics</i> , 2015, 47, 864-871.	9.4	451
84	Mutational dynamics between primary and relapse neuroblastomas. <i>Nature Genetics</i> , 2015, 47, 872-877.	9.4	253
85	<i>IGF2BP1</i> Harbors Prognostic Significance by Gene Gain and Diverse Expression in Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 1285-1293.	0.8	55
86	Neoadjuvant/adjuvant treatment of high-risk retinoblastoma: a report from the German Retinoblastoma Referral Centre. <i>British Journal of Ophthalmology</i> , 2015, 99, 949-953.	2.1	17
87	Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment. <i>Clinical Cancer Research</i> , 2015, 21, 3327-3339.	3.2	76
88	WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma. <i>Cancer Research</i> , 2015, 75, 5143-5154.	0.4	88
89	Telomerase activation by genomic rearrangements in high-risk neuroblastoma. <i>Nature</i> , 2015, 526, 700-704.	13.7	478
90	The Lin28/let-7 axis is critical for myelination in the peripheral nervous system. <i>Nature Communications</i> , 2015, 6, 8584.	5.8	36

#	ARTICLE	IF	CITATIONS
91	miR-542b exerts tumor suppressive functions in neuroblastoma by downregulating <i>urvivin</i> . <i>International Journal of Cancer</i> , 2015, 136, 1308-1320.	2.3	78
92	MYCN-targeting miRNAs are predominantly downregulated during MYCN-driven neuroblastoma tumor formation. <i>Oncotarget</i> , 2015, 6, 5204-5216.	0.8	38
93	Sensitivity to cdk1-inhibition is modulated by p53 status in preclinical models of embryonal tumors. <i>Oncotarget</i> , 2015, 6, 15425-15435.	0.8	37
94	CASP8 SNP D302H (rs1045485) Is Associated with Worse Survival in MYCN-Amplified Neuroblastoma Patients. <i>PLoS ONE</i> , 2014, 9, e114696.	1.1	15
95	ALK pERKs Up MYCN in Neuroblastoma. <i>Science Signaling</i> , 2014, 7, pe27.	1.6	0
96	Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1867-1870.	0.8	5
97	Early Targets of miR-34a in Neuroblastoma. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 2114-2131.	2.5	29
98	p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas. <i>Human Molecular Genetics</i> , 2014, 23, 6826-6837.	1.4	21
99	Robust Selection of Cancer Survival Signatures from High-Throughput Genomic Data Using Two-Fold Subsampling. <i>PLoS ONE</i> , 2014, 9, e108818.	1.1	6
100	Neuroblastoma in dialog with its stroma: NTRK1 is a regulator of cellular cross-talk with Schwann cells. <i>Oncotarget</i> , 2014, 5, 11180-11192.	0.8	26
101	Long-term follow-up of pediatric patients receiving total body irradiation before hematopoietic stem cell transplantation and post-transplant survival of >2 years. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1792-1797.	0.8	35
102	The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma. <i>Acta Neuropathologica Communications</i> , 2013, 1, 19.	2.4	26
103	The BCL2-938 promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia. <i>BMC Cancer</i> , 2013, 13, 452.	1.1	8
104	MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A. <i>International Journal of Cancer</i> , 2013, 133, 1064-1073.	2.3	91
105	Identifying transcriptional miRNA biomarkers by integrating high-throughput sequencing and real-time PCR data. <i>Methods</i> , 2013, 59, 154-163.	1.9	10
106	Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma. <i>International Journal of Cancer</i> , 2013, 132, E106-15.	2.3	26
107	Histone deacetylase 10 promotes autophagy-mediated cell survival. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E2592-601.	3.3	168
108	MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma. <i>Nucleic Acids Research</i> , 2013, 41, 6018-6033.	6.5	87

#	ARTICLE	IF	CITATIONS
109	Chemoreduction improves eye retention in patients with retinoblastoma: a report from the German Retinoblastoma Reference Centre. <i>British Journal of Ophthalmology</i> , 2013, 97, 1277-1283.	2.1	23
110	Expression of NTRK1/TrkA affects immunogenicity of neuroblastoma cells. <i>International Journal of Cancer</i> , 2013, 133, 908-919.	2.3	20
111	Neuroblastoma tumorigenesis is regulated through the Nm23-H1/h-Prune C-terminal interaction. <i>Scientific Reports</i> , 2013, 3, 1351.	1.6	34
112	Focal DNA Copy Number Changes in Neuroblastoma Target MYCN Regulated Genes. <i>PLoS ONE</i> , 2013, 8, e52321.	1.1	37
113	BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. <i>Oncotarget</i> , 2013, 4, 2080-2095.	0.8	122
114	Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas. <i>Neuro-Oncology</i> , 2012, 14, 859-869.	0.6	48
115	Targeted Expression of Mutated ALK Induces Neuroblastoma in Transgenic Mice. <i>Science Translational Medicine</i> , 2012, 4, 141ra91.	5.8	147
116	Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers. <i>Genome Biology</i> , 2012, 13, R95.	13.9	64
117	Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation. <i>Nature Cell Biology</i> , 2012, 14, 958-965.	4.6	79
118	LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. <i>Nature Genetics</i> , 2012, 44, 1199-1206.	9.4	336
119	<i>Dickkopf3</i> is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma. <i>International Journal of Cancer</i> , 2012, 130, 2591-2598.	2.3	43
120	Identification of a novel recurrent 1q42.2-4q12qter deletion in high risk MYCN single copy 11q deleted neuroblastomas. <i>International Journal of Cancer</i> , 2012, 130, 2599-2606.	2.3	37
121	CD57 ^{high} Neuroblastoma Cells Have Aggressive Attributes Ex Situ and an Undifferentiated Phenotype in Patients. <i>PLoS ONE</i> , 2012, 7, e42025.	1.1	14
122	Regulatory <i>BCL2</i> promoter polymorphism (rs938C>A) is associated with adverse outcome in patients with prostate carcinoma. <i>International Journal of Cancer</i> , 2011, 129, 2390-2399.	2.3	39
123	miRNA Expression Profiling Enables Risk Stratification in Archived and Fresh Neuroblastoma Tumor Samples. <i>Clinical Cancer Research</i> , 2011, 17, 7684-7692.	3.2	92
124	Polo-Like Kinase 1 is a Therapeutic Target in High-Risk Neuroblastoma. <i>Clinical Cancer Research</i> , 2011, 17, 731-741.	3.2	67
125	High <i>ALK</i> Receptor Tyrosine Kinase Expression Supersedes <i>ALK</i> Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma. <i>Clinical Cancer Research</i> , 2011, 17, 5082-5092.	3.2	95
126	MiR-34a Targeting of Notch Ligand Delta-Like 1 Impairs CD15+/CD133+ Tumor-Propagating Cells and Supports Neural Differentiation in Medulloblastoma. <i>PLoS ONE</i> , 2011, 6, e24584.	1.1	149

#	ARTICLE	IF	CITATIONS
127	Accurate prediction of neuroblastoma outcome based on miRNA expression profiles. <i>International Journal of Cancer</i> , 2010, 127, 2374-2385.	2.3	88
128	A small kiss of death for cancer. <i>Nature Medicine</i> , 2010, 16, 1079-1081.	15.2	6
129	Chromosomal and MicroRNA Expression Patterns Reveal Biologically Distinct Subgroups of 11q ^â Neuroblastoma. <i>Clinical Cancer Research</i> , 2010, 16, 2971-2978.	3.2	70
130	The miR-17-92 MicroRNA Cluster Regulates Multiple Components of the TGF- β Pathway in Neuroblastoma. <i>Molecular Cell</i> , 2010, 40, 762-773.	4.5	279
131	Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature. <i>Clinical Cancer Research</i> , 2010, 16, 1532-1541.	3.2	86
132	Production of Chick Embryo Extract for the Cultivation of Murine Neural Crest Stem Cells. <i>Journal of Visualized Experiments</i> , 2010, , .	0.2	18
133	Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma. <i>Nucleic Acids Research</i> , 2010, 38, 5919-5928.	6.5	183
134	Meta-analysis of Neuroblastomas Reveals a Skewed <i>ALK</i> Mutation Spectrum in Tumors with <i>MYCN</i> Amplification. <i>Clinical Cancer Research</i> , 2010, 16, 4353-4362.	3.2	243
135	Lysine-Specific Demethylase 1 Is Strongly Expressed in Poorly Differentiated Neuroblastoma: Implications for Therapy. <i>Cancer Research</i> , 2009, 69, 2065-2071.	0.4	405
136	Stabilization of N-Myc Is a Critical Function of Aurora A in Human Neuroblastoma. <i>Cancer Cell</i> , 2009, 15, 67-78.	7.7	464
137	The low-affinity neurotrophin receptor, p75, is upregulated in ganglioneuroblastoma/ganglioneuroma and reduces tumorigenicity of neuroblastoma cells <i>in vivo</i> . <i>International Journal of Cancer</i> , 2009, 124, 2488-2494.	2.3	15
138	MicroRNAs in the pathogenesis of neuroblastoma. <i>Cancer Letters</i> , 2009, 274, 10-15.	3.2	37
139	Reanalysis of neuroblastoma expression profiling data using improved methodology and extended follow-up increases validity of outcome prediction. <i>Cancer Letters</i> , 2009, 282, 55-62.	3.2	10
140	MYCN regulates oncogenic MicroRNAs in neuroblastoma. <i>International Journal of Cancer</i> , 2008, 122, 699-704.	2.3	251
141	Expression of the TrkA or TrkB receptor tyrosine kinase alters the double-strand break (DSB) repair capacity of SY5Y neuroblastoma cells. <i>DNA Repair</i> , 2008, 7, 1757-1764.	1.3	18
142	Transcription factor AP2alpha (TFAP2a) regulates differentiation and proliferation of neuroblastoma cells. <i>Cancer Letters</i> , 2008, 271, 56-63.	3.2	29
143	Translating Expression Profiling into a Clinically Feasible Test to Predict Neuroblastoma Outcome. <i>Clinical Cancer Research</i> , 2007, 13, 1459-1465.	3.2	28
144	Microarray analysis reveals differential gene expression patterns and regulation of single target genes contributing to the opposing phenotype of TrkA- and TrkB-expressing neuroblastomas. <i>Oncogene</i> , 2005, 24, 165-177.	2.6	76

#	ARTICLE	IF	CITATIONS
145	Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. <i>Oncogene</i> , 2005, 24, 7902-7912.	2.6	113
146	The neurotrophin receptor TrkB cooperates with c-Met in enhancing neuroblastoma invasiveness. <i>Carcinogenesis</i> , 2005, 26, 2105-2115.	1.3	65
147	Biological effects of TrkA and TrkB receptor signaling in neuroblastoma. <i>Cancer Letters</i> , 2005, 228, 143-153.	3.2	106
148	Functional genomics and target gene validation in experimental and human disease. <i>Drug Discovery Today: Technologies</i> , 2004, 1, 105-111.	4.0	0
149	MYCN and MicroRNAs. <i>Pediatric and Adolescent Medicine</i> , 0, , 35-46.	0.4	0
150	DNA Copy Number Changes and Beyond. <i>Pediatric and Adolescent Medicine</i> , 0, , 10-22.	0.4	0